vs
Ally Financial Inc.（ALLY）とAmphastar Pharmaceuticals, Inc.（AMPH）の財務データ比較。上の社名をクリックして会社を切り替えられます
Ally Financial Inc.の直近四半期売上が大きい（$301.0M vs $183.1M、Amphastar Pharmaceuticals, Inc.の約1.6倍）。Ally Financial Inc.の純利益率が高く（108.6% vs 13.3%、差は95.3%）。Amphastar Pharmaceuticals, Inc.の前年同期比売上増加率が高い（-1.8% vs -3.2%）。過去8四半期でAlly Financial Inc.の売上複合成長率が高い（11.1% vs 3.2%）
Ally Financial Inc.はアメリカ合衆国デラウェア州に設立登記され、ミシガン州デトロイトに本社を置く銀行持株会社です。自動車金融、ダイレクトバンクによるオンラインバンキング、企業向け融資、車両保険、住宅ローンのほか、分割販売やリース契約といった関連金融サービスを提供しています。
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
ALLY vs AMPH — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $301.0M | $183.1M |
| 純利益 | $327.0M | $24.4M |
| 粗利率 | — | 46.8% |
| 営業利益率 | — | 19.4% |
| 純利益率 | 108.6% | 13.3% |
| 売上前年比 | -3.2% | -1.8% |
| 純利益前年比 | 333.6% | -35.7% |
| EPS（希薄化後） | $0.97 | $0.51 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $301.0M | $183.1M | ||
| Q3 25 | $308.0M | $191.8M | ||
| Q2 25 | $312.0M | $174.4M | ||
| Q1 25 | $323.0M | $170.5M | ||
| Q4 24 | $311.0M | $186.5M | ||
| Q3 24 | $319.0M | $191.2M | ||
| Q2 24 | $324.0M | $182.4M | ||
| Q1 24 | $244.0M | $171.8M |
| Q4 25 | $327.0M | $24.4M | ||
| Q3 25 | $398.0M | $17.4M | ||
| Q2 25 | $352.0M | $31.0M | ||
| Q1 25 | $-225.0M | $25.3M | ||
| Q4 24 | $-140.0M | $38.0M | ||
| Q3 24 | $357.0M | $40.4M | ||
| Q2 24 | $294.0M | $37.9M | ||
| Q1 24 | $157.0M | $43.2M |
| Q4 25 | — | 46.8% | ||
| Q3 25 | — | 51.4% | ||
| Q2 25 | — | 49.6% | ||
| Q1 25 | — | 50.0% | ||
| Q4 24 | — | 46.5% | ||
| Q3 24 | — | 53.3% | ||
| Q2 24 | — | 52.2% | ||
| Q1 24 | — | 52.4% |
| Q4 25 | — | 19.4% | ||
| Q3 25 | — | 13.2% | ||
| Q2 25 | — | 24.2% | ||
| Q1 25 | -87.9% | 21.9% | ||
| Q4 24 | 56.3% | 24.2% | ||
| Q3 24 | 73.0% | 29.8% | ||
| Q2 24 | 79.3% | 30.3% | ||
| Q1 24 | 70.1% | 27.9% |
| Q4 25 | 108.6% | 13.3% | ||
| Q3 25 | 129.2% | 9.0% | ||
| Q2 25 | 112.8% | 17.8% | ||
| Q1 25 | -69.7% | 14.8% | ||
| Q4 24 | -45.0% | 20.4% | ||
| Q3 24 | 111.9% | 21.1% | ||
| Q2 24 | 90.7% | 20.8% | ||
| Q1 24 | 64.3% | 25.1% |
| Q4 25 | $0.97 | $0.51 | ||
| Q3 25 | $1.18 | $0.37 | ||
| Q2 25 | $1.04 | $0.64 | ||
| Q1 25 | $-0.82 | $0.51 | ||
| Q4 24 | $-0.54 | $0.74 | ||
| Q3 24 | $1.06 | $0.78 | ||
| Q2 24 | $0.86 | $0.73 | ||
| Q1 24 | $0.42 | $0.81 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $10.0B | $282.8M |
| 総負債低いほど良い | $17.1B | $608.7M |
| 株主資本純資産 | $15.5B | $788.8M |
| 総資産 | $196.0B | $1.6B |
| 負債/資本比率低いほどレバレッジが低い | 1.10× | 0.77× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $10.0B | $282.8M | ||
| Q3 25 | $10.2B | $276.2M | ||
| Q2 25 | $10.6B | $231.8M | ||
| Q1 25 | $10.4B | $236.9M | ||
| Q4 24 | $10.3B | $221.6M | ||
| Q3 24 | $8.6B | $250.5M | ||
| Q2 24 | $7.4B | $217.8M | ||
| Q1 24 | $8.2B | $289.6M |
| Q4 25 | $17.1B | $608.7M | ||
| Q3 25 | $16.7B | $608.6M | ||
| Q2 25 | $15.9B | $607.7M | ||
| Q1 25 | $16.5B | $603.9M | ||
| Q4 24 | $17.5B | $601.6M | ||
| Q3 24 | $16.8B | $596.4M | ||
| Q2 24 | $16.0B | $586.9M | ||
| Q1 24 | $17.0B | $594.0M |
| Q4 25 | $15.5B | $788.8M | ||
| Q3 25 | $15.1B | $776.7M | ||
| Q2 25 | $14.5B | $757.5M | ||
| Q1 25 | $14.2B | $751.3M | ||
| Q4 24 | $13.9B | $732.3M | ||
| Q3 24 | $14.7B | $727.7M | ||
| Q2 24 | $13.9B | $713.3M | ||
| Q1 24 | $13.7B | $672.4M |
| Q4 25 | $196.0B | $1.6B | ||
| Q3 25 | $191.7B | $1.7B | ||
| Q2 25 | $189.5B | $1.6B | ||
| Q1 25 | $193.3B | $1.6B | ||
| Q4 24 | $191.8B | $1.6B | ||
| Q3 24 | $193.0B | $1.5B | ||
| Q2 24 | $192.5B | $1.5B | ||
| Q1 24 | $192.9B | $1.6B |
| Q4 25 | 1.10× | 0.77× | ||
| Q3 25 | 1.11× | 0.78× | ||
| Q2 25 | 1.09× | 0.80× | ||
| Q1 25 | 1.16× | 0.80× | ||
| Q4 24 | 1.26× | 0.82× | ||
| Q3 24 | 1.14× | 0.82× | ||
| Q2 24 | 1.15× | 0.82× | ||
| Q1 24 | 1.25× | 0.88× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $640.0M | $32.9M |
| フリーキャッシュフロー営業CF - 設備投資 | — | $24.6M |
| FCFマージンFCF / 売上 | — | 13.4% |
| 設備投資強度設備投資 / 売上 | — | 4.5% |
| キャッシュ転換率営業CF / 純利益 | 1.96× | 1.35× |
| 直近12ヶ月FCF直近4四半期 | — | $121.2M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $640.0M | $32.9M | ||
| Q3 25 | $1.2B | $52.6M | ||
| Q2 25 | $947.0M | $35.6M | ||
| Q1 25 | $940.0M | $35.1M | ||
| Q4 24 | $620.0M | $29.0M | ||
| Q3 24 | $992.0M | $60.0M | ||
| Q2 24 | $1.6B | $69.1M | ||
| Q1 24 | $1.3B | $55.3M |
| Q4 25 | — | $24.6M | ||
| Q3 25 | — | $47.2M | ||
| Q2 25 | — | $25.0M | ||
| Q1 25 | — | $24.4M | ||
| Q4 24 | — | $16.6M | ||
| Q3 24 | — | $46.2M | ||
| Q2 24 | — | $63.1M | ||
| Q1 24 | — | $46.5M |
| Q4 25 | — | 13.4% | ||
| Q3 25 | — | 24.6% | ||
| Q2 25 | — | 14.3% | ||
| Q1 25 | — | 14.3% | ||
| Q4 24 | — | 8.9% | ||
| Q3 24 | — | 24.1% | ||
| Q2 24 | — | 34.6% | ||
| Q1 24 | — | 27.1% |
| Q4 25 | — | 4.5% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 6.1% | ||
| Q1 25 | — | 6.3% | ||
| Q4 24 | — | 6.7% | ||
| Q3 24 | — | 7.2% | ||
| Q2 24 | — | 3.3% | ||
| Q1 24 | — | 5.1% |
| Q4 25 | 1.96× | 1.35× | ||
| Q3 25 | 3.02× | 3.03× | ||
| Q2 25 | 2.69× | 1.15× | ||
| Q1 25 | — | 1.39× | ||
| Q4 24 | — | 0.76× | ||
| Q3 24 | 2.78× | 1.48× | ||
| Q2 24 | 5.36× | 1.82× | ||
| Q1 24 | 8.54× | 1.28× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ALLY
| Noninsurance Contracts | $242.0M | 80% |
| Brokerage Commissionsand Other | $21.0M | 7% |
| Commercial Portfolio Segment | $19.0M | 6% |
| Other | $13.0M | 4% |
| Banking Fees And Interchange Income | $5.0M | 2% |
| Brokered Agent Commissions | $1.0M | 0% |
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
